Stifel Reiterates Buy Rating on DexCom (DXCM)

Raymond James Reiterates Strong Buy Rating on DexCom (DXCM), PT $99, 'we believe the stock should be strong today'

Raymond James analyst Jayson Bedford reiterated a Strong Buy rating and $99.00 price target on DexCom (NASDAQ: DXCM)

The analyst comments "This morning, DXCM received FDA clearance for its 15-day G7 sensor. While the timing was in line with expectations, investor concerns had been mounting. We expect DXCM to launch the 15-day in 2H25 with pump compatibility. The sensor is cleared for people 18+. Consistent timeline: The clearance and launch timing are very consistent with managements prior commentary, which we find encouraging and credibility-boosting. Answers investor skepticism: Our sense is that investors had become... More

BTIG Reiterates Buy Rating on DexCom (DXCM)

BTIG analyst Marie Thibault reiterated a Buy rating and $120.00 price target on DexCom (NASDAQ: DXCM).

The analyst comments "Earlier this morning, Dexcom announced that the 15- day G7 sensor received FDA approval for use in patients 18 years and above with diabetes. The approval was supported by data showing an overall MARD of... More

DexCom (DXCM) G7 15 Day Receives FDA Clearance

DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today the FDA has cleared the Dexcom G7 15 Day Continuous Glucose Monitoring System for people over the age of 18 with diabetes in the United States. With an overall MARD of 8.0%,3 Dexcom G7 15 Day builds on the... More

Mizuho Starts DexCom (DXCM) at Outperform

(Updated - April 9, 2025 4:16 PM EDT)

Mizuho analyst Anthony Petrone initiates coverage on DexCom (NASDAQ: DXCM) with a Outperform rating and a price target of $85.00.

The analyst comments "Our OP rating on DXCM is predicated on positive survey data for continued continuous glucose... More